Ocean Biomedical, Inc.
OCEA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OCEA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OCEA
Ocean Biomedical, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics from academic research, with a pipeline in oncology, fibrosis, and infectious diseases, and no approved products or revenue to date.
Key risk: Cash runway and funding needs
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2025.
Ocean Biomedical, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics from academic research, with a pipeline in oncology, fibrosis, and infectious diseases, and no approved products or revenue to date.
- Ocean Biomedical has not generated any revenue from product sales and has incurred significant operating losses since inception [sec_mda · as of 2025-05-15].
- The company's pipeline includes clinical-stage programs, with plans to move certain preclinical candidates into the clinic within 12 to 24 months [sec_mda · as of 2025-05-15].
- As of 2025-03-31, the company reported cash & equivalents of $0.8M, net income of -$8.2M, and shareholders' equity of -$92.4M [sec].
- Ocean Biomedical's business model is based on licensing inventions from research universities and medical centers, including partnerships with Brown University and Rhode Island Hospital [sec_mda · as of 2025-05-15].
What works
- The company has established partnerships with academic institutions like Brown University and Rhode Island Hospital, providing access to breakthrough discoveries [sec_mda · as of 2025-05-15].
- Ocean Biomedical employs a multi-disciplinary approach to drug discovery, leveraging expertise across programs and disease areas [sec_mda · as of 2025-05-15].
- The company plans to exploit multiple commercialization options, including internal advancement, partnerships, and spin-outs, to maximize each program's value [sec_mda · as of 2025-05-15].
What to weigh
- Ocean Biomedical has no revenue from product sales and has incurred significant operating losses since inception, with a net loss of -$8.2M for the quarter ended 2025-03-31 [sec].
- The company has a very limited cash position of $0.8M as of 2025-03-31, which may require additional funding to continue operations and advance programs [sec].
- The successful development and commercialization of product candidates is highly uncertain due to numerous risks, including preclinical and clinical trial outcomes, regulatory approvals, and manufacturing [sec_mda · as of 2024-11-25].
- Shareholders' equity is negative at -$92.4M as of 2025-03-31, indicating accumulated deficits and potential financial instability [sec].
From the filings
Quoted directly from source documents.
The company has not generated any revenue from product sales.
“We have not generated any revenue from product sales.”
SEC MD&A · May 15, 2025
Ocean Biomedical plans to move certain preclinical candidates into the clinic in the next 12 to 24 months.
“We anticipate moving certain preclinical product candidates in our oncology, fibrosis and/or infectious disease programs into the clinic in the next 12 to 24 months.”
SEC MD&A · May 15, 2025
The company's business model includes licensing from academic institutions.
“Harnessing inventions and technologies from research universities and medical centers.We are experienced at identifying and sourcing breakthrough discoveries at academic and research institutions, including our current partnerships with Brown University and Rhode Island Hospital.”
SEC MD&A · May 15, 2025
Ocean Biomedical has incurred significant operating losses since inception.
“We have incurred significant operating losses since inception.”
SEC MD&A · May 15, 2025
Risks & what to watch (4)›
Key risks
- Cash runway and funding needs — Cash of $0.8M as of 2025-03-31 may be insufficient to fund operations, requiring additional capital to avoid delays or reductions in programs [sec].
- No revenue or approved products — The company has no product revenue and depends entirely on successful development and commercialization of candidates, which is highly uncertain [sec_mda · as of 2025-05-15].
- Negative shareholders' equity — Shareholders' equity of -$92.4M as of 2025-03-31 indicates accumulated deficits and potential financial distress [sec].
- Clinical and regulatory risks — Success depends on preclinical and clinical trial outcomes, regulatory approvals, and manufacturing, all of which are uncertain [sec_mda · as of 2024-11-25].
What to watch
- Progress of preclinical candidates moving into the clinic within 12 to 24 months, particularly in oncology, fibrosis, and infectious disease programs [sec_mda · as of 2025-05-15].
- Ability to raise additional capital through public offerings or other means to fund operations and development [sec_mda · as of 2024-11-25].
- Any updates on partnerships or licensing agreements with academic institutions like Brown University and Rhode Island Hospital [sec_mda · as of 2025-05-15].
- Financial performance and cash position in upcoming quarterly reports, given the low cash balance as of 2025-03-31 [sec].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Ocean Biomedical, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ocean Biomedical, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.5 months
OCF -$356K · Net income -$8M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 21, 2026- % of float
- 2.0%
- Days to cover
- 0.1
- Shares short
- 2,930,195
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OCEA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ocean Biomedical, Inc.?
Ocean Biomedical, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics from academic research, with a pipeline in oncology, fibrosis, and infectious diseases, and no approved products or revenue to date.
Who is the CEO of Ocean Biomedical, Inc.?
Michelle Berrey, M.D. is the chief executive officer of Ocean Biomedical, Inc. (OCEA).
Where is Ocean Biomedical, Inc. headquartered?
Ocean Biomedical, Inc. (OCEA) is headquartered in Providence, RI, United States.
What therapeutic areas does Ocean Biomedical, Inc. focus on?
Ocean Biomedical, Inc. develops therapies across Oncology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.